Related Experiment Video
Updated: May 10, 2026

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
Managed care implications of age-related ocular conditions
William J Cardarelli1, Roderick A Smith
1Atrius Health/Harvard Vanguard Medical Associates, Watertown, MA, USA. William_Cardarelli@vmed.org.
Abstract:
The economic costs of age-related ocular diseases and vision loss are increasing rapidly as our society ages. In addition to the direct costs of treating age-related eye diseases, elderly persons with vision loss are at significantly increased risk for falls and fractures, experiencing social isolation, and suffering from an array of comorbid medical conditions compared with individuals with normal vision. Recent studies estimate the total economic burden (direct and indirect costs) of adult vision impairment in the United States at $51.4 billion. This figure is expected to increase as the baby boomer generation continues to age. While a number of highly effective new therapies have caused a paradigm shift in the management of several major age-related ocular diseases in recent years, these treatments come at a substantial cost. This article reviews the economic burdens and treatment-related costs of 4 major ocular diseases of aging-glaucoma, age-related macular degeneration, diabetic retinopathy, and dry eye disease-and the implications for managed care.
More Related Videos
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Photoreceptors and Visual Pathways
Drug Dosing: Geriatric Patients
Glaucoma: Overview
Pharmacodynamics in Geriatric Patients: Effects of Age
Accessory Structures of the Eye
